<DOC>
	<DOC>NCT00885170</DOC>
	<brief_summary>The study will evaluate the both the efficacy of odanacatib on Bone Mineral Density (BMD) and the safety of odanacatib for postmenopausal osteoporosis in patients previously treated with alendronate</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (0822-042)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Patient has been postmenopausal for at least 5 years Patient has taken or is taking alendronate Patient agrees not to use medications for osteoporosis other than what is provided by the study Patient has a history or evidence of hip fracture Patient has a history of cancer within 5 years of screening, except certain skin or cervical cancers. Patient has active parathyroid disease Patient has a history of thyroid disease not adequately controlled by medication Patient is taking antiseizure medication and has abnormal calcium metabolism Patient has received any bisphosphonate other than alendronate for 20% of the last 3 years, or within 3 months of screening</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>